ProfileGDS5678 / 1434150_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 87% 90% 92% 92% 90% 91% 94% 93% 93% 87% 91% 89% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1043290
GSM967853U87-EV human glioblastoma xenograft - Control 26.7283287
GSM967854U87-EV human glioblastoma xenograft - Control 37.2816890
GSM967855U87-EV human glioblastoma xenograft - Control 47.7214792
GSM967856U87-EV human glioblastoma xenograft - Control 57.6445592
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9149490
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2751591
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.2029494
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.786793
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8861493
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5815487
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4310991
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.956989
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.785988